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Background: Nucleoside reverse transcriptase inhibitors (NRTIs) are the cornerstone of
the antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency
syndrome (HIV/AIDS). However, their use is sometimes limited by the development of a
painful sensory neuropathy, which does not respond well to drugs. Smoked cannabis
has been reported in clinical trials to have efficacy in relieving painful HIV-associated
sensory neuropathy.
Objectives: The aim of this study was to evaluate whether the expression of
endocannabinoid system molecules is altered during NRTI-induced painful neuropathy,
and also whether endocannabinoids can attenuate NRTI-induced painful neuropathy.
Methods: BALB/c mice were treated with 25 mg/kg of 2′,3′-dideoxycytidine (ddC,
zalcitabine), a NRTI, to induce thermal hyperalgesia. The expression of endocannabinoid
system molecules was evaluated by real time polymerase chain reaction in the brain,
spinal cord and paw skin at 6 days post ddC administration, a time point when mice had
developed thermal hyperalgesia. The effects of the endocannabinoids, N-arachidonoyl
ethanolamine (AEA) and 2-arachidonoyl glycerol (2-AG), the cannabinoid type 1 (CB1)
receptor antagonist AM 251, CB2 receptor antagonist AM 630, and G protein-coupled
receptor 55 (GPR55) antagonists ML193 and CID 16020046 on ddC-induced thermal
hyperalgesia were evaluated using the hot plate test.
Results: ddC treatment resulted in thermal hyperalgesia and increased transcripts of
the synthesizing enzyme Plcβ1 and decreased Daglβ in the paw skins, but not Napepld,
and Daglα compared to vehicle treatment. Transcripts of the inactivating enzymes Faah
and Mgll were downregulated in the brain and/or paw skin but not in the spinal cord of
ddC-treated mice. Both AEA and 2-AG had antihyperalgesic effects in mice with ddC-
induced thermal hyperalgesia, but had no effect in ddC-naïve mice. The antihyperalgesic
activity of AEA was antagonized by AM251 and AM630, whereas the activity of 2-AG
was antagonized by AM251, ML193 and CID 16020046, but not by AM630.
Conclusion: These data show that ddC induces thermal hyperalgesia, which is
associated with dysregulation of the mRNA expression of some endocannabinoid
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system molecules. The endocannabinoids AEA and 2-AG have antihyperalgesic activity,
which is dependent on cannabinoid receptor and GPR55 activation. Thus, agonists
of cannabinoid receptors and GPR55 could be useful therapeutic agents for the
management of NRTI-induced painful sensory neuropathy.
Keywords: endocannabinoid, 2-arachidonoyl glycerol, anandamide, neuropathic pain, hyperalgesia, ddC,
nucleoside reverse transcriptase inhibitor, antiretroviral
INTRODUCTION
Pain is a major cause of poor quality of life among human
immunodeficiency virus (HIV) infected patients (Larue et al.,
1997). It can be due to the HIV infection, opportunistic
infections, cancers and drug treatment (Nair et al., 2009).
Pain is almost underestimated as it is subjective especially in
HIV/acquired immune deficiency syndrome (AIDS) patients
where the main focus is on other principal symptoms of
the infection such as immunosuppression and opportunistic
infections (Larue et al., 1997; Ferrari et al., 2006). About
25–50% of all pain clinic visits are due to neuropathic pain
(Verma et al., 2004). Neuropathic pain is felt by around
20–40% of people with AIDS (Hitchcock et al., 2008; Ebirim
and Otokwala, 2013). Some of the symptoms of neuropathic
pain include hyperalgesia (an increased response to normally
painful stimuli), allodynia (pain triggered by normally non-
painful stimuli, such as cloth rubbing against the skin) and
spontaneous sensations such as burning, shooting, numbness,
spasm and prickling (Dworkin et al., 2003; Cherry et al., 2012).
It particularly affects the feet, hands and face, thus it can make
the performance of day to day tasks such as cooking and
other physical tasks very difficult (Hitchcock et al., 2008). This
can have a serious negative impact on psychosocial well-being
and overall quality of life of patients. These symptoms might
also lead to discontinuation of antiretroviral therapy resulting
in failure to suppress viral replication and worsening of HIV
infection/AIDS.
Nucleoside reverse transcriptase inhibitors (NRTIs), in
combination with other antiretroviral drugs, are effective in
controlling the replication of HIV and form the backbone of
most regimens used in the treatment of HIV/AIDS. However,
their use is sometimes hampered by adverse effects including the
development of dose-dependent painful peripheral neuropathy.
Some NRTIs, such as didanosine (ddI), stavudine (d4T),
and zalcitabine (ddC), have been removed/are being removed
from regimens because of the development of peripheral
neuropathy in about 15–30% of patients (Fichtenbaum et al.,
1995; Moyle and Sadler, 1998; Dalakas, 2001). First-line
medications recommended for managing neuropathic pain
include amitriptyline, nortriptyline, duloxetine, venlafaxine,
gabapentin, pregabalin, and 5% topical lidocaine (Dworkin
et al., 2007). However, patients are not satisfied with current
treatment options because of inadequate pain relief (Shlay
et al., 1998; Simpson et al., 2000; Phillips et al., 2010) and
the adverse side effect profiles which limit therapeutic efficacy
and contribute to poor pain relief (Rahn and Hohmann, 2009).
However, some HIV patients with painful neuropathy report
relief after using cannabis (Woolridge et al., 2005; Phillips et al.,
2010). Smoked cannabis has been reported in two randomized
clinical trials to have efficacy in relieving painful HIV-associated
sensory neuropathy (Abrams et al., 2007; Ellis et al., 2009). It
has been observed that treatment with cannabinoid receptor
agonists such as WIN 55,212-2 produced antinociception and
antihyperalgesia in rodent models of HIV and NRTI-induced
neuropathic pain (Wallace et al., 2007a,b). However, neither
changes in the endocannabinoid system nor the effects of
endocannabinoids against NRTI-induced painful neuropathy
have been investigated.
Endocannabinoids and exogenous cannabinoid ligands
produce their effects via two known cannabinoid receptors, CB1
and CB2 receptors (Guindon and Hohmann, 2009). Endogenous
cannabinoid ligands are lipid molecules that are produced from
phospholipid precursors in the cell membrane (Di Marzo et al.,
1998; Piomelli, 2005) upon an “on demand” fashion (Giuffrida
et al., 1999; Varma et al., 2001; Kim et al., 2002). N-arachidonoyl-
ethanolamine (anandamide, AEA) and 2-arachidonoyl-glycerol
(2-AG) are the two most extensively studied endocannabinoids so
far (Di Marzo and Piscitelli, 2015). AEA is a partial agonist at the
CB1 and CB2 receptors (Hillard et al., 1999; Howlett et al., 2002;
Chavez et al., 2010; Grueter et al., 2010). On the other hand, 2-AG
behaves as a complete agonist at CB1 and 2 receptors (Stella et al.,
1997; Gonsiorek et al., 2000; Savinainen et al., 2001; Howlett
et al., 2002). Several pathways are involved in the synthesis
of AEA and 2-AG (Di Marzo, 2008). N-acylphosphatidyl
ethanolamine specific phospholipase D (NAPE-PLD) hydrolyses
N-arachidonylphosphatidyl ethanolamine (NAPE) to produce
AEA and phosphatidic acid (Natarajan et al., 1981; Schmid
et al., 1983; Di Marzo et al., 1994; Okamoto et al., 2004). 2-AG
is synthesized through the catalysis of the membrane bound
phosphatidylinositol-4,5-biphosphate (PIP2) to diacylglycerol
(DAG) by phospholipase C (PLC)-β1 (Farooqui et al., 1989;
Ayakannu et al., 2013; Di Marzo and Piscitelli, 2015). The
intermediate DAG is further catalyzed by the action of one of two
diacylglycerol lipases (DAGLs), DAGL-α and DAGL-β, to 2-AG
(Bisogno et al., 2003; Tanimura et al., 2010). In order to maintain
endocannabinoid homeostasis, AEA and 2-AG after release in
the synaptic space are either transported back into the cells by
a transporter or degraded by enzymes. AEA is hydrolyzed to
arachidonic acid and ethanolamine by fatty acid amide hydrolase
(FAAH), an intracellular membrane-bound enzyme (Cravatt
et al., 1996). 2-AG is hydrolyzed to arachidonic acid and glycerol
by the enzyme monoacylglycerol lipase (MAGL) (Dinh et al.,
2002; Saario et al., 2004).
The objective of this study was to evaluate whether the
expression of molecules of the endocannabinoid system is
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altered in the central nervous system (CNS) and the periphery
of mice during NRTI-induced painful neuropathy, and also
whether endocannabinoids can attenuate NRTI-induced painful
neuropathy.
MATERIALS AND METHODS
Animals
The animals used in this study were female BALB/c mice
(2–3 months old; 20–25 g) supplied by the Animal Resources
Centre at the Health Sciences Centre (HSC), Kuwait University,
Kuwait. The mice were kept in temperature controlled (24± 1◦C)
rooms with food and water ad libitum. All experiments were
performed during the same period of the day (8:00 AM to
4:00 PM) to exclude diurnal variations in pharmacological
effects. The animals were handled in compliance with Directive
2010/63/EU of the European Parliament and of the Council on
the protection of animals used for scientific purposes. All animal
experiments were approved by the Ethical Committee for the use
of Laboratory Animals in Teaching and in Research, HSC, Kuwait
University.
Administration of 2′,3′-Dideoxycytidine
(ddC) to Induce Neuropathic Pain
2′,3′-dideoxycytidine (ddC, zalcitabine) (Sigma-Aldrich, St.
Louis, MO, USA) was prepared freshly in normal saline (0.9%
NaCl) on the day of the experiment. ddC 25 mg/kg or its
vehicle was administered to mice in a single intraperitoneal (i.p.)
injection, in a volume of 10 ml/kg. This treatment regimen has
been reported to produce painful neuropathy in mice (Sanna
et al., 2014).
Drug Administration
All the drugs were purchased from Tocris, Bristol, UK.
N-arachidonoyl ethanolamine (AEA, anandamide), was dissolved
in Tocrisolve; 2-arachidonoyl glycerol (2-AG) in normal saline
containing 5% ethanol, 5% cremophor, and 5% DMSO (Guindon
et al., 2011); AM 251 and AM 630 in normal saline containing 5%
Tween 80 and 5% propylene glycol; ML193 and CID 16020046
in normal saline containing 5% ethanol, 5% cremophor, and
5% DMSO. The drugs and their vehicles were freshly prepared
and further diluted with normal saline to lower concentrations
before administration and administered i.p. to mice at a volume
of 10 ml/kg body mass.
The doses of AEA and 2-AG, 1, 10, and 20 mg/kg, were
chosen based on those previously shown to have antinociceptive
and/or antihyperalgesic activity in mice (Mechoulam et al., 1995;
Calignano et al., 2001). The drugs were administered to naïve
mice and ddC-treated mice at 6 days after administration of ddC,
when mice had developed thermal hyperalgesia.
To evaluate the receptors involved in the antihyperalgesic
activities of the endocannabinoids CB1 (AM 251 3 mg/kg), CB2
(AM 630 3 mg/kg), and GPR55 (ML193 and CID 16020046 both
at 10 mg/kg) antagonists were administered 15 min before the
administration of AEA and 2-AG to mice with ddC-induced
thermal hyperalgesia.
Assessment of Thermal Nociception
Reaction latencies of mice to hot plate (Panlab SL, Barcelona,
Spain) at 55 ± 1◦C in the form of the first sign of nociception,
paw licking, flinching or jump response to avoid the heat were
measured, as described before (Parvathy and Masocha, 2013),
before (baseline latency), at day 6 after injection of ddC and at
various times after drug treatment. A cut-off period of 20 s was
maintained to avoid damage to the paws.
Tissue Preparation and Real Time
RT-PCR
Mice were anesthetized with halothane, sacrificed by decapitation
on day 6 post-administration of ddC. Brains, spinal cords and
paw skins were dissected, snap frozen in liquid nitrogen and kept
at - 70◦C prior to mRNA extraction.
Gene transcripts of cannabinoid type 1 receptor (Cnr1),
Cnr2, N-arachidonoyl ethanolamine-specific phospholipase D
(Napepld), phospholipase C-beta 1 (Plcβ1), diacylglycerol lipase-
alpha (Daglα), Daglβ , fatty acid amide hydrolase (Faah), and
monoacylglycerol lipase (Mgll) were quantified in the brains,
spinal cords and paw skins of vehicle-treated and ddC-treated
mice by real time polymerase chain reaction (PCR). Total RNA
was extracted from the fresh frozen brains, spinal cords and paw
skins using the RNeasy Kit (Qiagen GmbH), reverse-transcribed,
and the mRNA levels were quantified on an ABI Prism R© 7500
sequence detection system (Applied Biosystems) as previously
described (Masocha, 2009). The primer sequences which were
used, listed in Table 1, were ordered from Invitrogen (Life
Technologies) and/or synthesized at the Research Core Facility
(RCF), HSC, Kuwait University. Threshold cycle (Ct) values for
all cDNA samples were obtained and the amount of mRNA of
individual animal sample (n = 5–10 per group) was normalized
to Ppia (cyclophilin A, housekeeping gene) (1Ct). The relative
amount of target gene transcripts was calculated using the
2−11Ct method as described previously (Livak and Schmittgen,
2001). These values were then used to calculate the mean and
standard error of mean of the relative expression of the target
gene mRNA in the brains, spinal cords and paw skins of vehicle-
and ddC-treated mice.
Statistical Analyses
Statistical analyses were performed using unpaired Student’s
t-test (to compare the effects of ddC to those of the vehicle on
mRNA expression on day 6 post ddC injection; and to compare
the effects of ddC on reaction latency on day 6 post-injection
and pretreatment reaction latency), one-way analysis of variance
(ANOVA) followed by Bonferroni’s multiple comparison post-
tests (to compare the effects of pretreatment with CB receptor
and GPR55 antagonists before administration of either AEA or
2-AG to the antihyperalgesic effects of AEA and 2-AG in mice
with ddC-induced thermal hyperalgesia at day 6 post-injection
of ddC), or two-way repeated measures ANOVA followed by
Bonferroni’s multiple comparison post-tests (to compare the
effects of ddC to vehicle on reaction latency over time; and to
compare the effects of AEA and 2-AG to that of the vehicle in
mice with ddC-induced thermal hyperalgesia) using GraphPad
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TABLE 1 | Polymerase chain reaction (PCR) primer sequences of cyclophilin A and endocannabinoid system molecules.
Gene Polarity
Sense Anti-sense
Sequence 5′–3′ Sequence 5′–3′
Ppia (cyclophilin A) GCTTTTCGCCGCTTGCT CTCGTCATCGGCCGTGAT
Cnr1 (CB1 receptor) GTTCTGATCCTGGTGGTGTTG GTTCAGCAGGCAGAGCATAC
Cnr2 (CB2 receptor) TCTGGAAAGCCCACCGGCATGTAG CAAGGCACAGCATGGAACAGAAGG
Daglα GTCCTGCCAGCTATCTTCCTC CGTGTGGGTTATAGACCAAGC
Daglβ AGCGACGACTTGGTGTTCC GCTGAGCAAGACTCCACCG
Faah GCTGTGCTCTTTACCTACCTG GAAGCATTCCTTGAGGCTCAC
Mgll TGATTTCACCTCTGGTCCTTG GTCAACCTCCGACTTGTTCC
Napepld GGGCGGCTCTCACTTTCTA ACACTTGTGCTTATAGGTCATTTAAT
Plcβ1 GCCCCTGGAGATTCTGGAGT GGGAGACTTGAGGTTCACCTTT
FIGURE 1 | 2′,3′-Dideoxycytidine (ddC)-induced thermal hyperalgesia in female BALB/c mice. Reaction latency of mice before treatment and at day 6
post-injection (6 dpi) of ddC in a hot plate test. Each bar represents the mean ± SEM of values obtained from 18 animals. ∗∗p < 0.01 compared to drug vehicle at
the same day after treatment (two-way repeated measures ANOVA followed by Bonferroni’s Multiple Comparison Test) and ##p < 0.01 compared to pretreatment
baseline values (Student’s t-test).
Prism software (version 5.0). The differences were considered
significant at p < 0.05. The results in the text and figures are
expressed as the means± SEM.
RESULTS
ddC-Induced Thermal Hyperalgesia in
Female BALB/c Mice
Mice treated with ddC developed thermal hyperalgesia on day 6
after treatment, i.e., reduction in reaction latency compared to the
baseline latency and vehicle-treated mice (7.3 ± 0.5 s compared
to 12.7 ± 0.9 s and 12.8 ± 1.0 s, respectively; n = 18 for both
vehicle- and ddC-treated mice; p < 0.001 for both comparisons;
Figure 1). There was a significant interaction between treatment
and time after treatment with ddC (F1,34 = 60.72, p< 0.0001).
The mRNA expression of endocannabinoid molecules (in the
brain, spinal cord, and paw skin) and the antihyperalgesic activity
the endocannabinoids AEA and 2-AG were analyzed at day 6
in separate groups of mice, at this time point mice showed
ddC-induced thermal hyperalgesia.
Expression of the Endocannabinoid
System Molecules mRNA during
ddC-Induced Thermal Hyperalgesia in
the Brain, Spinal Cord, and Paw Skin
Treatment with ddC did not affect the expression of
endocannabinoid-synthesizing enzymes (Napepld, Plcβ1, Daglα,
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FIGURE 2 | Effects of ddC on endocannabinoid system molecules transcript levels in the brain, spinal cord and paw skin of female BALB/c mice.
Relative mRNA expression of (A) endocannabinoid-synthesizing enzymes Napepld, Plcβ1, Daglα and Daglβ, (B) endocannabinoid-inactivating enzymes Faah and
Mgll, and (C) cannabinoid receptors Cnr1 and Cnr2 in the brains, spinal cords, and paw skins of BALB/c mice on day 6 after administration of the ddC or its vehicle.
Each bar represents the mean ± SEM of the values obtained from 6 to 10 vehicle-treated mice and 5–8 ddC-treated mice. ∗p < 0.05, ∗∗p < 0.01 compared to
vehicle-treated mice (Student’s t-test).
and Daglβ) in the brain or the spinal cord compared to vehicle
treatment. However, treatment with ddC significantly increased
the transcripts of Plcβ1 (p= 0.0021), decreased the transcripts of
Daglβ (p= 0.0406), but did not significantly affect the expression
of Daglα and Napepld (p > 0.05) in the paw skin compared to
vehicle treatment (Figure 2A).
Treatment with ddC did not affect the expression of
endocannabinoid-inactivating enzymes (Faah and Mgll) in the
spinal cord compared to vehicle treatment. However, treatment
with ddC significantly decreased the transcripts of Faah
(p= 0.0055), but did not significantly affect the expression of Mgll
(p> 0.05) in the brain compared to vehicle treatment. In the paw
skin, treatment with ddC significantly decreased the transcripts of
Mgll (p = 0.0275), but did not significantly affect the expression
of Faah (p> 0.05; Figure 2B).
The expression of the cannabinoid receptors Cnr1 and Cnr2
were not significantly modulated by treatment with ddC in all the
three tissues analyzed, brain, spinal cord and paw skin, compared
to vehicle treatment (p> 0.05; Figure 2C).
Effects of Treatment with the
Endocannabinoids AEA and 2-AG on
Naïve Mice and Mice with ddC-Induced
Thermal Hyperalgesia
Mice with ddC-induced thermal hyperalgesia and naïve mice
were treated with 1, 10, and 20 mg/kg of the endocannabinoids
AEA and 2-AG.
The intraperitoneal administration of vehicle did not change
the reaction latency to thermal stimuli in mice with ddC-
induced thermal hyperalgesia compared to before administration
at day 6 (p > 0.05; Figures 3A,B). However, all the doses
(1, 10, and 20 mg/kg) of AEA and 2-AG administered produced
significant increase in reaction latency in mice with ddC-
induced thermal hyperalgesia at all time points from 10
to 70 min post-drug administration, when the experiment
was terminated, compared to mice treated with vehicle and
before endocannabinoid administration at day 6 (p < 0.01;
Figures 3A,B). There was a significant interaction between
treatment and time after treatment for AEA doses of 1 mg/kg
(F7,98 = 50.22, p< 0.0001), 10 mg/kg (F7,98 = 73.17, p< 0.0001),
and 20 mg/kg (F7,98 = 48.48, p < 0.0001) in mice with
ddC-induced thermal hyperalgesia. There was also a significant
interaction between treatment and time after treatment for 2-
AG doses of 1 mg/kg (F7,98 = 662.69, p < 0.0001), 10 mg/kg
(F7,98 = 218.53, p < 0.0001) and 20 mg/kg (F7,98 = 1230.23,
p< 0.0001) in mice with ddC-induced thermal hyperalgesia.
The intraperitoneal administration of AEA or 2-AG did not
change the reaction latency to thermal stimuli in naïve mice
(without ddC treatment) at any time point compared to mice
treated with vehicle and before endocannabinoid administration
(p > 0.05; Figures 3C,D). There was no significant interaction
between treatment and time after treatment for AEA doses of
1 mg/kg (F7,105 = 0.55, p= 0.7928) and 10 mg/kg (F7,105 = 0.48,
p = 0.8456), but at 20 mg/kg (F7,105 = 2.61, p = 0.0155) in
mice with ddC-induced thermal hyperalgesia. There was also
no significant interaction between treatment and time after
treatment for 2-AG doses of 1 mg/kg (F7,98 = 0.79, p = 0.5996),
and 20 mg/kg (F7,98 = 1.07, p= 0.3871) in naïve mice.
Effects of Cannabinoid Receptor and
GPR55 Antagonists on the
Antihyperalgesic Activities of the
Endocannabinoids AEA and 2-AG in Mice
with ddC-Induced Thermal Hyperalgesia
The administration of the CB1 receptor antagonist AM 251
(3 mg/kg) or the CB2 antagonist AM 630 (3 mg/kg) to mice
with ddC-induced thermal hyperalgesia did not alter the reaction
latency to hot-plate test compared to vehicle-treated mice at
30 min post-treatment (p> 0.05; Figure 4).
The CB1 receptor antagonist AM 251 significantly
antagonized the antihyperalgesic effect of both AEA and 2-
AG, i.e., a 38% reduction in reaction latency to AEA, 13.1± 0.1 s
for AEA alone compared to 8.2 ± 0.2 s for AEA + AM 251
and 33% reduction in reaction latency to 2-AG, 11.7 ± 0.3 s for
2-AG compared to 7.9 ± 0.3 s for 2-AG + AM 251 (p < 0.01;
Figures 4A,B).
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FIGURE 3 | Antihyperalgesic effects of AEA and 2-AG in female BALB/c mice with ddC-induced thermal hyperalgesia. Reaction latency times at day 6
post-injection of ddC at different times after treatment with (A) AEA (1, 10, and 20 mg/kg) or its vehicle, and (B) 2-AG (1, 10, and 20 mg/kg) or its vehicle in a
hot-plate test. Reaction latency times of naïve mice at different times after treatment with (C) AEA (1, 10, and 20 mg/kg) or its vehicle, and (D) 2-AG (1 and
20 mg/kg) or its vehicle in a hot-plate test. Each bar represents the mean ± SEM of values obtained from 8 to 9 animals. ∗∗p < 0.01 compared to drug vehicle at the
same time point after treatment (two-way repeated measures ANOVA followed by Bonferroni’s Multiple Comparison Test).
The CB2 receptor antagonist AM 630 significantly
antagonized the antihyperalgesic effect of AEA but not 2-
AG, i.e., a 11% reduction in reaction latency to AEA, 13.1± 0.1 s
for AEA alone compared to 11.7 ± 0.3 s for AEA + AM 630
(p < 0.01; Figure 4A) and no difference in reaction latency to
2-AG, 11.7 ± 0.3 s for 2-AG compared to 12.0 ± 0.4 s for 2-AG
+ AM 630 (p> 0.05; Figure 4B).
Since the antihyperalgesic activity of 2-AG was partially
antagonized by the CB1 receptor antagonist but was not affected
by the CB2 receptor antagonist, and 2-AG has been reported
to activate GPR55 (Ryberg et al., 2007), the effects of two
GPR55 antagonists CID 16020046 and ML193 on the activities
of 2-AG were also evaluated. The administration of the GPR55
antagonists CID 16020046 (10 mg/kg) and ML193 (10 mg/kg)
to mice with ddC-induced thermal hyperalgesia did not alter
the reaction latency to hot-plate test compared to vehicle-treated
mice at 30 min post-treatment (p> 0.05; Figure 4C). The GPR55
antagonists CID 16020046 and ML193 significantly antagonized
the antihyperalgesic effect of 2-AG, i.e., a 48% reduction in
reaction latency to 2-AG caused by pretreatment with CID
16020046, 11.2 ± 0.1 s for 2-AG alone compared to 5.8 ± 0.04 s
for 2-AG+ CID 16020046 and 49% reduction in reaction latency
to 2-AG caused by pretreatment with ML193, 11.2 ± 0.1 s for 2-
AG alone compared to 5.7 ± 0.1 s for 2-AG +ML193 (p < 0.01;
Figure 4C).
DISCUSSION
This study presents the first data on antihyperalgesic activities
of endocannabinoids and the expression of endocannabinoid
molecules mRNA in the CNS and periphery during NRTI-
induced thermal hyperalgesia. Mice with ddC-induced thermal
hyperalgesia had altered mRNA expression of endocannabinoid-
synthesizing enzymes Plcβ1 and Daglβ in the paw skin, and
endocannabinoid-inactivating enzymes Faah and Mgll in the
brain and paw skin, respectively. The endocannabinoids AEA
and 2-AG had antihyperalgesic activity against ddC-induced
thermal hyperalgesia but had no activity in naïve mice. The
antihyperalgesic activity of AEA was dependent on activation
of both CB1 and CB2 receptors, whereas that of 2-AG was
dependent on CB1 receptor and GPR55, but not CB2 receptor.
Changes in endocannabinoid expression have been found in
various models of neuropathic pain (Jhaveri et al., 2007). In the
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FIGURE 4 | Effects of CB receptor and GPR55 antagonists on the antihyperalgesic effects of AEA and 2-AG in female BALB/c mice with ddC-induced
thermal hyperalgesia at day 6 post-injection of ddC. Effects of (A) a CB1 receptor antagonist AM 251 and a CB2 receptor antagonist AM 630 on the
antihyperalgesic effects of AEA, (B) a CB1 receptor antagonist AM 251 and a CB2 receptor antagonist AM 630 on the antihyperalgesic effects of 2-AG, and
(C) GPR55 antagonists CID 16020046 and ML193 on the antihyperalgesic effects of 2-AG in BALB/c mice with ddC-induced thermal hyperalgesia 30 min after
administration in the hot plate test. Each bar represents the mean ± SEM of values obtained from 8 to 16 animals.∗∗p < 0.01 compared to drug vehicle at the same
time point after treatment and ##p < 0.01 to mice treated with AEA or 2-AG at the same time point after treatment (one-way ANOVA followed by Bonferroni’s
Multiple Comparison Test).
periphery, AEA has been found to be increased in the paw skin
and dorsal root ganglia (DRG) of rats with spinal nerve ligation
(SNL)-induced painful neuropathy (Mitrirattanakul et al., 2006;
Jhaveri et al., 2007). 2-AG has been found to be increased
in the DRG of rats with SNL-induced painful neuropathy
(Mitrirattanakul et al., 2006). In the CNS, AEA, and/or 2-AG
have been reported to be increased in different areas of the brain
and spinal cord of rats with neuropathic pain induced by chronic
constriction injury (CCI) of the sciatic nerve (Palazzo et al., 2006;
Petrosino et al., 2007). In an animal model of chemotherapy-
induced neuropathic pain (CINP) AEA and 2-AG were increased
in the spinal cord, whilst 2-AG, but not AEA, was decreased in
the paw skin (Guindon et al., 2013). Endocannabinoid molecules,
such as AEA and 2-AG, are synthesized in an on demand fashion
(Luchicchi and Pistis, 2012). Thus, changes in the enzymes that
synthesize or degrade them would have a significant effect on
the amount of endocannabinoids available when needed. There
were no changes in the expression of mRNA of Napepld, the
main AEA synthesizing enzyme, in DRGs or in the spinal cord
of rats with CCI-induced neuropathic pain (Malek et al., 2014).
However, NAPE-PLD immunoreactivity was decreased in the
DRGs of rats with SNL (Sousa-Valente et al., 2016). In the current
study, ddC-induced neuropathic pain did not significantly affect
the level of the mRNA of Napepld in the CNS or periphery, similar
to what has been found in the CCI model (Malek et al., 2014).
However, there was an increase in the mRNA expression of Plcβ1,
an enzyme involved in the synthesis of DAG, an intermediate in
the synthesis of 2-AG, in mice with ddC-induced neuropathic
pain in the periphery but not in the CNS. On the other hand, there
were no changes in the expression of mRNA of Plcβ1 mRNA in
DRGs or in the spinal cord of rats with CCI-induced neuropathic
pain (Malek et al., 2014). The protein levels of DAGL-α, one
of the main enzymes involved in the synthesis of 2-AG from
DAG, were decreased in the spinal cord of mice with diabetic
neuropathic pain (Ikeda et al., 2013). In the current study, the
mRNA expression of Daglβ , but not Daglα, was decreased in
the paw skin but not spinal cord or brain of mice with ddC-
induced neuropathic pain. The mRNA expression of Faah, the
main enzyme in the degradation of AEA, was increased in the
spinal cord but not in the DRGs (Malek et al., 2014). Similarly, in
a rat model of CINP Faah was increased in the spinal cord but not
in the paw skin (Guindon et al., 2013). FAAH immunoreactivity
was increased in the DRGs of rats with SNL (Sousa-Valente et al.,
2016). In the rostroventromedial medulla (RVM) area of the
brain of rats with diabetic neuropathy FAAH protein levels were
increased (Silva et al., 2016). In contrast, mRNA expression of
Faah was decreased in the brain but not the spinal cord, and
showed a tendency toward decrease in the paw skin of mice with
ddC-induced thermal hyperalgesia. There were no changes in the
mRNA expression of Mgll, the main enzyme in the degradation
of 2-AG, in the spinal cord or paw skins of rats with CINP
(Guindon et al., 2013). In contrast mRNA expression of Mgll
was decreased in the paw skin, but not spinal cord and brain, of
mice with ddC-induced thermal hyperalgesia. The findings of the
current study show a unique characteristic of a decrease in the
mRNA expression of the enzymes that inactivate AEA and 2-AG,
which might result in low levels of the enzymes and increased
endocannabinoids.
N-arachidonoyl ethanolamine and 2-AG are important
endogenous inhibitors of nociception (Rodriguez de Fonseca
et al., 2005; Guindon and Hohmann, 2009). Exogenous
administration locally in the paw skin of both AEA and
2-AG in rats with partial sciatic nerve ligation (PNL)- or
diabetes-induced neuropathic pain and intrathecally into the
spinal cord of rats with CCI-induced neuropathic pain have
produced antihyperalgesic activities (Guindon and Beaulieu,
2006; Desroches et al., 2008; Schreiber et al., 2012; Starowicz
et al., 2012; Desroches et al., 2014). In the current study,
systemic administration (i.p.) of both AEA and 2-AG produced
antihyperalgesic activities and abrogated ddC-induced thermal
hyperalgesia, but had no activity in naïve mice (mice without
neuropathic pain). Calignano et al. (1998) observed that
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locally administered AEA had antinociceptive effects, whereas
intraperitoneally administered AEA had no effect on nociception
in naïve mice. However, in another study they observed that
intraperitoneally administered AEA had antinociceptive effects
that lasted up to 20 min (Calignano et al., 2001). In another
study, AEA administered intraperitoneally did not produce
antinociceptive effects in rats (Costa et al., 1999). Our findings
of antihyperalgesic activity of AEA and 2-AG administered
intraperitoneally, that lasted up to 70 min when the experiment
was terminated, in mice with ddC-induced thermal hyperalgesia
but not in naïve mice suggest that possibly the reduction
in the inactivating enzymes FAAH and MAGL in mice with
ddC-induced thermal hyperalgesia contributed to the prolonged
antihyperalgesic activity of the endocannabinoids. This is in line
with a study that showed that administration of AEA to mice
that lack FAAH (FAAH−/− mice) produced antinociception but
AEA did not have antinociceptive effects in wild-type (FAAH+/+
mice) (Cravatt et al., 2001).
N-arachidonoyl ethanolamine and 2-AG produce their effects
via two known cannabinoid receptors, CB1 and CB2 receptors
(Guindon and Hohmann, 2009). AEA has been reported to
produce its antinociceptive effects via activation of both CB1
and CB2 receptors (Schreiber et al., 2012). However, other
studies have shown that AEA produces its antinociceptive
effects via activation of CB1 receptors but not CB2 receptors
(Calignano et al., 1998; Guindon and Beaulieu, 2006).
Pre-treatment with either a CB1 or CB2 antagonist antagonized
the antihyperalgesic activity of AEA in mice with ddC-induced
thermal hyperalgesia. The antagonism was much more with the
CB1 antagonist than the CB2 antagonist, thus suggesting that
AEA had antihyperalgesic activity mainly via CB1 receptors
although CB2 receptors also had a minor role. Pre-treatment
with a CB1 antagonist, but not a CB2 antagonist, antagonized
the antihyperalgesic activity of 2-AG in mice with ddC-
induced thermal hyperalgesia. Thus, suggesting that 2-AG had
antihyperalgesic activity via CB1 receptors but not CB2 receptors.
This is in contrast with a study done in rats with PNL-induced
neuropathic pain where both CB1 and CB2 antagonists equally
inhibited the antihyperalgesic effects of 2-AG administered
locally, subcutaneously in the dorsal surface of the hind paw
(Desroches et al., 2008, 2014). The current study shows that
CB1 receptors play a more important role than CB2 receptors in
the antihyperalgesic effects of both endocannabinoids AEA and
2-AG against ddC-induced hyperalgesia.
Since the antihyperalgesic activity of 2-AG was partially
antagonized by the CB1 receptor antagonist but was not
affected by the CB2 receptor antagonist, and 2-AG has been
reported to activate GPR55 (Ryberg et al., 2007), the effects
of two GPR55 antagonists CID 16020046 and ML193 were
also evaluated. We used two different antagonists of the same
receptors because we did not find any reports of GPR55
receptor antagonists on the antinociceptive or antihyperalgesic
activity of 2-AG. Pre-treatment with either GPR55 antagonist
inhibited the antihyperalgesic activity of 2-AG in mice with
ddC-induced thermal hyperalgesia much more than the CB1
receptor antagonist. Loss of GPR55 (GPR55−/−mice) resulted in
increased sensitivity to thermal nociception, thermal hyperalgesia
(Staton et al., 2008; Wu et al., 2013; Bjursell et al., 2016).
However, GPR55−/− mice did not develop PNL-induced
hyperalgesia, whereas the wild-type mice did, suggesting that
GPR55 has a pro-nociceptive activity (Staton et al., 2008).
Lysophosphatidylinositol (LPI), which is considered the main
endogenous agonist of GPR55 (Oka et al., 2007; Henstridge
et al., 2009), has pro-nociceptive activities (Deliu et al., 2015).
Thus, our results show that 2-AG, in contrast to LPI, produces
antinociceptive activity via activation of GPR55 receptors.
Possibly 2-AG and LPI bind to and activate GPR55 at different
sites or in different ways. This possibility warrants further
research.
CONCLUSION
Our results show that ddC induces thermal hyperalgesia that
is associated with dysregulation of the mRNA expression of
endocannabinoid molecules, more importantly downregulation
of Mgll and Faah, which are involved in the inactivation of the
endocannabinoids AEA and 2-AG. The endocannabinoids AEA
and 2-AG had antihyperalgesic activity against ddC-induced
thermal hyperalgesia, but had no activity in naïve mice, possibly
due to the reduced mRNA expression of Mgll and Faah in mice
with ddC-induced thermal hyperalgesia. The antihyperalgesic
activity of AEA was dependent on activation of both CB1
and CB2 receptors, whereas that of 2-AG was dependent on
CB1 receptors and GPR55, but not CB2 receptors. FAAH and
MAGL inhibitors might not be very useful in the treatment of
NRTI-induced neuropathic pain, since these two enzymes are
reduced during ddC-induced thermal hyperalgesia. However,
stable formulations of AEA and 2-AG or agonists of both CB1
receptors and GPR55, with activities similar to AEA and 2-AG,
might be useful in the treatment of NRTI-induced neuropathic
pain.
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